MEKINIST (trametinib), protein kinase inhibitor
ONCOLOGY - New indication
Opinions on drugs - Posted on Mar 18 2016
Reason for request
Moderate improvement as first-line treatment of unresectable or metastatic melanoma, in patients with a BRAF V600 mutation
- MEKINIST now has Marketing Authorisation in combination with dabrafenib, in the treatment of adults with unresectable or metastatic melanoma with a BRAF V600 mutation.
- Combining MEKINIST with dabrafenib improves progression-free survival and overall survival in comparison with dabrafenib alone.
Clinical Added Value
Évaluation des médicaments
HAS opinions and decisions